Sten R. Sörensen, CEO, will together with Rahul Agrawal, Chief Medical Officer and Head of R&D and Jeppe Øvlesen, Board Member, participate at the well-attended investor and networking event Biotech Showcase 2025. The conference takes place each year in San Francisco, in conjunction with the 43rd Annual J.P. Morgan Healthcare Conference, during one of the industry's largest gatherings and busiest weeks. The J. P. Morgan healthcare week attracts global business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. Sten R. Sörensen will also hold a Company presentation during Biotech Showcase 2025.

"We are honored to have been selected to present at Biotech Showcase, one of the industry's most prominent events for investment and partnerships. This opportunity allows us to showcase our recent milestones reflecting our commitment to advancing treatments for patients with rare cardiovascular and pulmonary diseases. We recently presented positive topline results from our Phase IIa study of CS1 in Pulmonary Arterial Hypertension demonstrating that CS1 is safe, well-tolerated with a positive impact on exploratory clinical efficacy parameters. We look forward to engaging with industry leaders and investors at the Biotech Showcase and during the course of the J.P. Morgan Healthcare week," said Sten R. Sörensen, CEO Cereno Scientific.

Details of Cereno's presentation:

Date: Monday, January 13, 2025

Time: 2:00 PM

Room: Yosemite C (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, San Francisco, CA (United States)

Read more about Biotech Showcase and the program here

About Biotech Showcase

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 17th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. The conference takes place each year in San Francisco, in parallel to the 43rd Annual J.P. Morgan Healthcare Conference, during one of the industry's largest gatherings and busiest weeks.

For further information, please contact:

Julia Fransson, Director Business Development

Email:  julia.fransson@cerenoscientific.com

Phone: +46 708-14 31 75

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.